Induction of anti-tumour lymphocytes in cancer patients after brief exposure to supernatants from cultures of anti-CD3-stimulated allogeneic lymphocytes

British Journal of Cancer

Volumn 76, Issue 8, 1997, Pages 1072-1080

  Baxevanis, C N ^a,b   Tsiatas, M L ^a   Cacoullos, N T ^a   Spanakos, G ^a   Liacos, C ^a   Missitzis, I ^a   Papadhimitriou, S I ^a   Papamichail, M ^a  

^a Hellenic Anticancer Institute   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Anti CD3 monoclonal antibody; Cancer immunotherapy; Cytokine; Cytotoxic lymphocyte; Peripheral blood mononuclear cell; Tumour infiltrating lymphocyte

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; SUPERNATANT;

EID: 0030766924     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.510     Document Type: Article

References (47)

1. Alexander JP, Kudoh S, Meslop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E and Bukowski RM (1993) T-cells infiltrating renal-cell carcinoma display a poor proliferation response even they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 53: 1380-1387
2. Anastasopoulos E, Reclos GJ, Baxevanis CN, Gritzapis AD, Tsilivakos V, Panagiotopoulos N, Fotiou S, Missitzis J, Karydas E and Papamichail M (1942) Monocyte disorders associated with T cell defects in patients with solid tumors. Anticancer Res 12: 489-494
3. Aoki T, Kikuchi H, Miyatake SI, Oda Y, Iwasaki K, Yamasaki T, Kinashi T and Honjo T (1989) Interleukin-5 enhances interleukin-2-mediated lymphokine-activated killer activity. J Exp Med 170: 583-592
4. Armitage RJ, Namen AE, Sassenfeld HM and Grabstein KH (1990) Regulation of human T cell proliferation by IL-7. J Immunol 144: 938-941
5. Balch CM, Tilden AB, Dougherty PA, Cloud G and Abu T (1983) Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg 198: 192-199
6. Baxevanis CN and Papamichail M (1994) Characterization of the anti-tumor immune response in human cancers and strategics for immunotherapy. Crit Rev Oncol Hematol 16: 157-179
7. Baxevanis CN, Reclos GJ, Gritzapis AD, Dedoussis GVZ, Missitzis I and Papamichail M (1993a) Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphocyte-activated killer cell function in patients with breast cancer. Cancer 72: 491-501
8. Baxevanis CN, Reclos GJ and Papamichail M (1993b) Prothymosin-α restores depressed allogeneic cell-mediated lympholysis and natural-killer-cell activity in patients with cancer. Int J Cancer 53: 264-268
9. Baxevanis CN, Reclos GJ, Gritzapis AD, Dedoussis GVZ, Arsenis P, Katsiyiannis A, Mitsis PG, Tsavaris N and Papamichail M (1993c) Comparison of immune parameters in patients with one or two primary malignant neoplasms. Nat Immun 12: 41-49
10. Baxevanis CN, Dedoussis GVZ, Papadopoulos NG, Missitzis I, Stathopoulos GP and Papamichail M (1994a) Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 74: 1275-1282
11. Baxevanis CN, Dedoussis GVZ, Gritzapis AD, Stathopoulos GP and Papamichail M (1994b). Interleukin-1β synergizes with interleukin 2 in the outgrowth of autologous tumor-reactive CD8+ effectors. Br J Cancer 70: 625-630
12. Baxevanis CN, Dedoussis GVZ, Papadopoulos NG, Missitzis I, Beroukas C, Stathopoulos GP and Papamichail M (1995) Enhanced human lymphokine- activated killer cell function after brief exposure to granulocyte macrophage- colony stimulating factor. Cancer 76: 1253-1260
13. Blanchard DK, Hall RE and Djeu JY (1990) Role of CD18 in lymphokine activated killer (LAK) cell-mediated lysis of human monocytes: comparison with other LAK targets. Int J Cancer 45: 312-329
14. Curti BD, Longo DL, Ochoa AC, Conlon KC, Smith JW, Alyord G, Creekmores SP, Fenton RG, Gause BL and Holmlund J (1993) Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J Clin Oncol 11: 652-660
15. Dranoff G, Jaffee E, Lazenby A, Golenmbek P, Levitsky H and Brose K (1993) Vaccination with irradiated tumor-cells engineered to secrete murine granulocyte-monocyte colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539-3543
16. Ettinghausen SE and Rosenberg SA (1995) Immunotherapy and gene therapy of cancer. Adv Surg 28: 223-254
17. Fiorentino DF, Zlotnik A, Mossmann TR, Howard M and O'Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147: 3815-3822
18. Fujiwara T and Grimm EA (1992) Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist. J Immunol 148: 2941-2946
19. Gamero AM, Ussery D, Reintgen DS, Puleo CA and Djeu JY (1995) Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Cancer Rev 55: 4988-4994
20. Gately MK, Gubler U, Brunda MJ, Nadeau RR, Anderson TD, Lipman JM and Sarmiento U (1994) Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol 1: 187-196
21. Geodegebuure PS, Zuber M, Leonard-Vidal DL, Burger UL, Cusak JC and Chang MP (1994) Reactivation of murine tumor-infiltrating lymphocytes with solid- phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy. Surg Oncol 3: 79-89
22. Goedegebuure PS, Douville LM, Li H, Richmond GC, Shoof DD, Scavone M and Eberlein TJ (1995) Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 13: 1939-1949
23. Kaneko T, Fusauch Y, Kakni Y, Okumura K, Mizoguchi H and Oshimi K (1994) Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells. Leuk Lymphoma 14: 219-229
24. Katsanis E, Xu Z, Anderson PM, Dancisak BB, Bausero MA, Weisdorf DJ, Blazar BR and Ochoa AC (1994) Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity. Bone Marrow Transplant 14: 563-572
25. Kim JA, Martin EW, Morgan CJ, Aldrich W and Triozzi PL (1995) Expansion of mucin-reactive T-helper lymphocytes from patients with colorectal cancer. Cancer Biother 10: 115-123
26. Kosmidis PA, Baxevanis CN, Tsavaris N, Papanastasiou M, Anastasopoulos E, Bacoyiannis C, Mylonakis N, Karvounis N, Bafaloukos SD, Karabellis A and Papamichail M (1992) The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alpha-2b. J Clin Oncol 7: 1153-1157
27. Mehrotra PT, Grant AJ and Siegel JP (1995) Synergistic effects of IL-7 and IL-12 on human T cell activation. J Immunol 154: 5093-5102
28. Miescher S, Whiteside TL, Moretta L and von Fliedner V (1987) Clonal and frequency analysis of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 138: 4004-4011
29. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L and von Fliedner V (1988) Proliferative and cytolytic potentials of purified human tumor-infiltrating T-lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer 42: 659-666
30. Monson JRT, Ramsden CW, Giles GR, Brennan TG and Guillon PJ (1987) Lymphokine-activated killer (LAK) cells in patients with gastrointestinal cancer. Gut 28: 420-425
31. Mule JJ, Smith GA and Rosenberg SA (1987) Interleukin-4 can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells. J Exp Med 166: 792-803
32. Nakajama F, Khanna A, Xu G, Lagman M, Haschemeyer R, Mouradian J, Wang JC, Stenzel KH, Rubin AL and Suthanthiran M (1994) Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: Stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression. Proc Natl Acad Sci USA 91: 7889-7893
33. Nostala CG, Edington HD, McKinney TG, Tahera H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD and Storkus WJ (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol 153: 1647-1706
34. Naume B and Espevik T (1991) Effects of IL-7 and IL-12 on highly enriched CD56+ natural killer cells: a comparative study. J Immunol 147: 2208-2213
35. Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, Parker B, Sawczuki Ross S and Krane RJ (1990) Effect of autolymphocyte therapy on survival and quality like in patients with metastatic renal-cell carcinoma. Lancet 335: 994-998
36. Owen-Schaub LB, Gutterman JV and Grimm EA (1988) Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin-2 in the generation of human-activated killer cell cytotoxicity. Cancer Res 48: 788-794
37. Papamichail M and Baxevanis CN (1992) Gamma-interferon enhances the cytotoxic activity of interleukin-2-induced LAK cells, TIL, and effusion-associated lymphocytes. J Chemother 4: 387-392
38. Porgador A, Bannerji R, Watanabe Y, Feldman V, Gilboa E and Eisenbach L (1993) Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J Immunol 150: 1458-1470
39. Sone S, Utsugi T, Mii A and Ogura T (1988) Differential effects of recombinant interferon alpha, beta, and gamma on the induction of human lymphokine (IL-2)-activated killer activity. J Natl Cancer Inst 80: 425-430
40. Suthantiran M, Williams PS, Solomon SD, Rubin AL and Stenzel KH (1984) Induction of cytolytic activity by anti-T3 monoclonal antibody. Activation of alloimmune memory cells and natural killer cells from normal and immunodeficient individuals. J Clin Invest 74: 2263-2271
41. Taga K, Mostowski H and Tosato G (1993) Human interleukin 10 can directly inhibit T-cell growth. Blood 81: 2964-2971
42. Tani M, Tanimura H, Yamane H, Mizobata S, Iwahashi M, Tsunoda T, Noguchi K, Tamai M, Hotta T and Teresawa H (1995) Generation of CD4+ cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int J Cancer 60: 802-807
43. Uberti JP, Joshi I, Ueda M, Martilotti F, Sensenbrenner LL and Lum LG (1994) Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: optimal conditions for the proliferation and induction of non MHC-restricted cytotoxicity. Clin Immunol Immunopathol 70: 234-240
44. Ubhi SS, Horsburgh T, Veitch PS and Bell PRF (1991) Anti-CD3 enhancement of cellular cytotoxicity in cancer patients treated with interleukin-2. Anticancer Res 11: 931-936
45. Ullman KS, Northrop JP, Verweji CL and Crabtree GR (1990) Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Anim Rev Immunol 8: 421-452
46. de Waal-Malefyt R, Yssel H and De Vries JE (1993) Direct effects of IL-10 subsets of human CD4+ T cell clones and resting T cell. Specific inhibition of IL-2 production and proliferation. J Immunol 150: 4754-4765
47. Yoshizawa H, Chang AE and Shu S (1992) Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin-2-activated tumor-activated tumor-draining lymph node cells. Cancer Res 52: 1129-1136